Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al

Affiliations

¹ University of California San Francisco Comprehensive Cancer Center, San Francisco, USA. Electronic address: Hope.Rugo@ucsf.edu.
² Global Outcomes and Evidence, New York, USA.
³ Medical Affairs, Pfizer Inc., New York, USA.

Free article

Comment

H S Rugo et al. Ann Oncol. 2018.

Free article

. 2018 Aug 1;29(8):1878.

doi: 10.1093/annonc/mdy206.

¹ University of California San Francisco Comprehensive Cancer Center, San Francisco, USA. Electronic address: Hope.Rugo@ucsf.edu.
² Global Outcomes and Evidence, New York, USA.
³ Medical Affairs, Pfizer Inc., New York, USA.

No abstract available

Comment on

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Rugo HS, et al. Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012. Ann Oncol. 2018. PMID: 29360932 Free PMC article. Clinical Trial.
Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missing.
Kaiser T, Köhler M, Wieseler B. Kaiser T, et al. Ann Oncol. 2018 Aug 1;29(8):1877. doi: 10.1093/annonc/mdy204. Ann Oncol. 2018. PMID: 29873692 Free PMC article. No abstract available.